WINDLAS BIOTECH LIMITED(WBI) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report).
With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility.
WINDLAS BIOTECH LIMITED provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.
In addition to providing services and products in the CDMO market, they also sell their own branded products in the trade generics and OTC markets as well as export generic products to several countries.
IPO – Opening 04 August 2021 , Closing- 06 August 2021 .
Shares Allotment – 11 August 2021
Initiation of Refunds- 12 August 2021
Credit of shares to Demat A/C – 13 August 2021 IPO Listing on 17 August 2021
To Open Demat to Apply IPO’s or Mutual Funds Register Below – Click here
For doing investments in Mutual funds, SIP, IPO’s , Insurance etc.
Call/WhatsApp 8860801116 or mail – contact@wealthfundas.com
